Drug Profile
Zeamatin
Latest Information Update: 19 Jun 2001
Price :
$50
*
At a glance
- Originator MycoLogics
- Class Antifungals
- Mechanism of Action Amylase inhibitors; Cell membrane permeability enhancers; Trypsin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 19 Jun 2001 No-Development-Reported for Mycoses in USA (Unknown route)
- 05 Oct 1998 New profile
- 05 Oct 1998 Preclinical development for Mycoses in USA (Unknown route)